Advertisement
Advertisement
TELO
Telomir Pharmaceuticals, Inc. Common Stock
1.16
USDSponsored
-0.01
-0.85%
Aug 07, 15:29 UTC -4
Closed
After-Market
1.18
+0.02
+1.29%
TELO Earnings Reports
Positive Surprise Ratio
TELO beat 2 of 5 last estimates.
40%
Next Report
In 3 Days
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.07
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-58.82%
Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 13, 2026, TELO reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.07 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Telomir Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Telomir Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Telomir Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Telomir Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analysts, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement